School of Biomedical Sciences
生物醫學學院
The Chinese University of Hong Kong 香港中文大學

陳文樂教授


Andrew lab a 教授

PhD.

電話:   3943 3771

電郵:   Email住址會使用灌水程式保護機制。你需要啟動Javascript才能觀看它

地址:

  407A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

Publons: https://publons.com/researcher/2608470/andrew-man-lok-chan/

ORCID: https://orcid.org/0000-0001-9923-5464

 

  

個人簡介

Prof. Andrew M. CHAN (陳文樂) is a cancer biologist.  He obtained his Ph.D. degree in Molecular Biology from the Institute of Cancer Research at the Royal Marsden Hospital, University of London.  He was a Fogarty International Fellow at the National Cancer Institute of the United States National Institutes of Health, and Faculty Members at the Mount Sinai School of Medicine and the Medical College of Wisconsin.  Professor Chan is currently a member of the Cancer Biology & Experimental Therapeutics Thematic Research Program.  Professor Chan serves on multiple governmental granting agencies and has published more than 70 peer-reviewed papers with some in high impact journals such as Science, Nature Genetics, Cancer Cell, PNAS, Blood, and Nature Neuroscience.  The laboratory of Professor Chan focuses on various cancer cell signaling pathways in the initiation and progression of human cancer.  His research involves understanding the regulatory mechanisms of the PTEN tumor suppressor in brain cancer and neurodevelopmental disorders, as well as the Ras-related GTPase, R-Ras, in tumor immune microenvironment.

  1. Cancer cell signaling. 
  2. PTEN tumor suppressor.
  3. Ras-related small GTPases.
  4. Tumor microenvironment.
  5. Tumor Immunity.
  6. Neurodevelopmental and Neurodegenerative disorders.
  7. Mouse models of human diseases.
Selected from a total of 74 publications.
  1. Bae, M., Roh, J.D., Kim, Y., Kim, S.S., Han, H.M., Yang, E., Kang, H., Lee, S., Kim, J.Y., Kang, R., Jung, H., Yoo, T., Kim, H., Kim, D., Oh, H., Han, S., Kim, D., Han, J., Bae, Y.C., Kim, H., Ahn, S., Chan, A.M., Lee, D., Kim, J.W. & Kim, E. (2021) SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function. EMBO Molecular Medicine, In Press.
  2. Wong, C.W., Wang, Y., Liu, T., Li, L., Cheung, S.K.K., Or, P.M., Cheng, A.S., Choy, K.W., Burbach, J.P.H., Feng, B., Chang, R.C.C., & Chan, A.M. (2020). Autism-associated PTEN missense mutation leads to enhanced nuclear localization and neurite outgrowth in an induced pluripotent stem cell line. FEBS J., 287, 4848-4861.
  3. Sanchez-Puelles, C., Calleja-Felipe, M., Ouro, A., Bougamra, G., Arroyo, A., Diez, I., Erramuzpe Aliaga, A., Cortes, J.M., Martinez-Hernandez, J., Lujan, R., Navarrete, M., Venero, C., Chan, A.M., Morales, M., Esteban, J., & Knafo, S. (2020). PTEN activity defines an axis for plasticity at cortico-amygdala synapses and determines social behaviour. Cerebral Cortex, 30, 505-524.
  4. Dukhinova, M., Veremeyko, T., Yung, A.W.Y., Kuznetsova, I.S., Lau, T.Y.B., Kopeikina, E., Chan, A.M., & Ponomarev, E.D. (2019) Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer’s disease. Neurobiol Aging. 77:128-143.
  5. Liu, T., Wang, Y., Wang, Y., & Chan, A.M. (2019). Multifaceted regulation of PTEN subcellular distributions and biological functions. Cancers, 11, 1247.
  6. Yan, M., Wang, Y., Wong, C.W., Or, P.M., Wong, K.L., Li, L., Many, A.M., Guan, H., Khoo, U.S., & Chan, A.M. (2018). PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model. Cancer Lett, 430, 67-78. 
  7. Zhang, C., He, X., Kwok, Y.K., Wang, F., Xue, J., Zhao, H., Suen, K.W., Wang, C.C., Ren, J., Chen, G.G., Lai, P.B.S., Li, J., Xia, Y., Chan, A.M., Chan, W.Y., & Feng, B. (2018). Homology-independent multiallelic disruption via CRISPR/Cas9-based knock-in yields distinct functional outcomes in human cells. BMC Biol., 16, 151. 
  8. Lee, Y.Y., Mok, M.T., Kang, W., Yang,W., Tang, W., Wu, F., Xu, L., Yan, M., Yu, Z., Lee, S.D., Tong, J.H.M., Cheung, Y.S., Lai, P.B.S., Yu, D. Y., Wang, Q., Wong, G.L. H., Chan, A.M., Yip, K.Y., To, K.F., & Cheng, A.S.L. (2018). Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. Nucleic Acids Res, 46, 8832-8847. 
  9. Wang, Y., Wong, C.W., Yan, M., Li, L., Liu, T., Or, P.M., Tsui, S.K., Waye, M.M., & Chan, A.M. (2018). Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Lett, 429, 54-65. 
  10. Wong, C.W., Or, P.M.-Y., Wang, Y., Li, L., Li, J., Yan, M., Cao, Y., Luk, H.M., Tong, T.M.F., Leslie, N.R., Lo, I.F.-M., Choy, R.K.W., & Chan, A.M. (2018). Identification of a PTEN mutation with reduced protein stability, phosphatase activity, and nuclear localization in Hong Kong patients with autistic features, neurodevelopmental delays and macrocephaly. Autism Research, 11, 1098-1109.
  11. Knafo, S., Sanchez-Puelles, C., Palomer, E., Delgado, I., Draffin, J.E., Mingo, J., Wahle, T., Kaleka, K., Mou, L., Pereda-Perez, I., Klosi, E., Faber, E.B., Chapman, H.M., Lozano-Montes, L., Ortega-Molina, A., Ordonez-Guiterrez, L., Wandosell, F., Vina, J., Dotti, C.G., Hall, R.A., Pulido, R., Gerges, N.Z., Chan, A.M., Spaller, M.R., Serrano, M., Venero, C., & Esteban, J.A. (2016). PTEN recruitment controls synaptic and cognitive function in Alzheimer’s models. Nature Neuroscience, 19, 443-453.
  12. Yan, X., He, Y., Chen, Y., Yu, M., Singh, G., Wang, D., Hillery, C.A., & Chan, A.M. (2015). R-Ras regulates Murine T cell migration to peripheral lymph nodes and chemokine-induced activation of lymphocyte function-associated antigen-1. Plos One, 10, e0145218.
  13. Ray, A., Basu, S., Miller, N.M., Chan, A.M., & Dittel, B.N. (2014). An increase in tolerogenic Dendritic Cell and natural T Regulatory Cell Numbers during EAE in Rras-/- mice results in attenuated disease. J Immunology, 192, 5109-5117.
  14. Worzfeld, T., Swiercz, J. M., Sentürk, A., Genz, B., Korostylev, A., Deng, S., Hoshino, M., Epstein, J.A., Ruoslahti, E., Chan, A.M., Vollmar, B., Acker-Palmer, A., Kuner, R., & Offermanns, S. (2014). Genetic dissection of plexin signalling in vivo. Proc Natl Acad Sci USA, 1111, 2194-2199.
  15. Kennedy, C.R., Tilkens, S.B., Guan, H., & Chan, A.M. (2013). Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. Cancer Letters, 336, 299-306.
  16. Singh, G., Hashimoto, D., Yan, X., Helft, J., Ma, G., Qiao, R.F., Kennedy, C.R., Chen, S.-H., Merad, M., & Chan, A.M. (2012). R-Ras is required for Murine Dendritic cell maturation and CD4+ T-cell priming. Blood, 119, 1693-1701.
  17. Odriozola, L., Singh, G., Hoang, T., & Chan, A.M. (2007). Regulation of PTEN Activity by its Carboxyl-terminal Autoinhibitory domain. J Biol Chem, 282, 23306-23315.
  18. Rodriguez, N.N., Lee, I.N., Banno, A., Qiao, H.F., Qiao, R.F., Hoang, T., Kimmelman, A.C., & Chan, A.M. (2006). Characterization of R-Ras3/M-Ras null mice reveals a potential role in trophic factor signaling. Mol Cell Biol, 26, 7145-7154.
  19. Kimmelman, A.C., Nuñez-Rodriguez, N., & Chan, A.M. (2002). R-Ras3/M-Ras induces Differentiation of PC12 cells through a Cell-Type Specific Activation of the Mitogen-Activated Protein Kinase. Mol Cell Biol, 22, 5946-5961.
  20. Chan, T.O., Rodeck, U., Chan, A.M., Kimmelman, A.C., Rittenhouse, S.E., Panayotou, G., & Tsichlis, P.N. (2002). Small GTPases and tyrosine kinases co-regulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell, 1, 181-191.
  21. Goutham N., Heath, K.E., Reeves, H.L., Li, D., Giono, L.E., Kimmelman, A.C., Glucksman, M.J., Narla, J., Eng, F.J., Chan, A.M., Ferrari, A.C., Martignetti, J.A., & Friedman, S.L. (2001). KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. Science, 294, 2563-2566.
  22. Tolkacehva, T., Boddapati, M., Sanfiz, A., Tsuchida, K., Kimmelman, A.C., & Chan, A.M. (2001). Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at Threonine codon 382 & 383. Cancer Research, 61, 4985-4989.
  23. Kimmelman, A.C., Osada, M., & Chan, A.M. (2000). R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene, 19, 2014-2022.
  24. Tolkacheva, T., & Chan, A.M. (2000). Inhibition of H-ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene. Oncogene, 19, 680-689.
  25. Osada, M., Tolkacheva, T., Li, W., Chan, T.O., Tsichlis, P.N., Saez, R., Kimmelman, A.C., & Chan, A.M. (1999). Differential Roles of Akt, Rac, and Ral in R-Ras-Mediated Cellular Transformation, Adhesion, and Survival. Mol Cell Biol, 19, 3336-3344.
  26. Kimmelman, A., Tolkacheva, T., Lorenzi, M.V., Osada, M., & Chan, A.M. (1997). Identification and characterization of R-ras3 : a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution. Oncogene, 15, 2675 – 2686.
  27. Clark, J., Rocques, P.J., Crew, A.J., Gill, S., Shipley, J., Chan, A.M., Gusterson, B.A., & Cooper, C.S. (1994). Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genetics, 7, 502-508.
  28. Chan, A.M., Miki, T., Meyers, K.A., & Aaronson, S.A. (1994). A new human oncogene of the ras superfamily unmasked by expression cDNA cloning. Proc Natl Acad Sci USA, 91, 7558-7562.
  29. Chan, A.M., Rubin, J.S., Bottaro, D.P., Hirschfield, D.W., Chedid, M., & Aaronson, S.A. (1991). Identification of a competitive HGF Antagonist Encoded by an Alternative Transcript. Science, 254, 1382-1385.
  30. Bottaro, D.P., Rubin, J.S., Falletto, D.L., Chan, A.M., Kmiecik, T.E., Vande Woude, G.F., & Aaronson, S.A. (1991). Identification of the HGF receptor as the c-met protooncogene product. Science, 251, 802-804.
  1. RGC - General Research Fund [PI; 01-Jan-20]: "PTEN regulated mitotic events as therapeutic targets in Glioblastoma" (HK$1,042,516).
  2. Innovation & Technology Fund-Midstream Research Programme for Universities [PI; 15-Jul-19]: "Identification of Small Molecules for the Treatment of Alzheimer's Disease" (HK$6,488,741).
  3. RGC - General Research Fund [PI; 01-Jan-19]: "The role of PTEN and YKL-40 in Alzheimer's Disease" (HK$691,295).
  4. RGC - General Research Fund [PI; 01-Jan-16 to 31-Dec-18]: "The Roles of a Small G-protein Signaling Pathway in Tumor Microenvironment" (HK$765,747).
  5. Health and Medical Research Fund [PI; 01-Apr-15 to 30-Jun-17]: "Targeted Drug Discovery for Alizheimer's Disease" (HK$727,564).
  6. RGC - Collaborative Research Fund (CRF) [PI; 01-Apr-15 to 30-Sep-18]: "Elucidating the Molecular Defects Associated with PTEN Mutations in Autism Spectrum Disorders" (HK$5,330,831).
  7. RGC - General Research Fund [PI; 01-Jan-15 to 31-Dec-17]: "Mechanisms of Stromal Mediated Chemoresistance in Neuroblastoma" (HK$892,112).
  8. RGC - General Research Fund [PI; 01-Jan-14 to 30-Apr-17]: "Novel Mechanisms of Breast Tumor Suppression by PTEN" (HK$777,377).

 

407A